- Home
- GH
as 12-20-2024 3:37pm EST
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | PALO ALTO |
| Market Cap: | 4.3B | IPO Year: | 2018 |
| Target Price: | $39.93 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $15.81 - $38.53 | Next Earning Date: | 11-06-2024 |
| Revenue: | $692,256,000 | Revenue Growth: | 29.20% |
| Revenue Growth (this year): | 32.23% | Revenue Growth (next year): | 16.90% |
Stock Insider Trading Activity of Guardant Health Inc. (GH)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Tariq Musa | GH | Director | Dec 18 '24 | Sell | $34.85 | 116 | $4,042.60 | 2,810 | |
| Joyce Meghan V. | GH | Director | Dec 2 '24 | Sell | $35.90 | 100 | $3,590.00 | 7,548 | |
| Kalia Kumud | GH | Chief Information Officer | Nov 18 '24 | Sell | $29.25 | 7,000 | $204,722.00 | 17,744 | |
| Joyce Meghan V. | GH | Director | Nov 13 '24 | Sell | $29.90 | 2,896 | $86,595.32 | 7,548 | |
| CLARK IAN T | GH | Director | Nov 12 '24 | Sell | $29.48 | 8,318 | $244,929.50 | 15,677 |
Latest Guardant Health Inc. News
GH Breaking Stock News: Dive into GH Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
Meaningful Insights Biotech Analytics (MiBA) and Guardant Health Announce Strategic Partnership to Optimize Use of Biomarker Testing and Data Analytics to Improve Cancer Care
MT Newswires
3 days ago
Guardant Health, COTA Collaborate to Provide Combined Data for Cancer Research
Business Wire
3 days ago
COTA and Guardant Health Partner to Advance Precision Oncology Research and Therapy Development with Real-World Clinicogenomic Data and AI Analytics
MT Newswires
4 days ago
Guardant Health, Boehringer Collaborate on Companion Test for Potential Lung Cancer Drug
Business Wire
4 days ago
Guardant Health Announces Collaboration With Boehringer Ingelheim to Develop Companion Diagnostic for Detection of Specific Mutations in Advanced Lung Cancer
Business Wire
13 days ago
Guardant Health to Share New Research Demonstrating Value of Liquid Biopsy Tests, Real-world Data and AI Analytics in Tailoring Treatment Approaches for Breast Cancer at 2024 San Antonio Breast Cancer Symposium
Simply Wall St.
17 days ago
Investors in Guardant Health (NASDAQ:GH) from three years ago are still down 61%, even after 8.6% gain this past week
MedTech Dive
20 days ago
Guardant awarded nearly $293M in false ad trial against Natera
Compare GH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GH Guardant Health Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.